Biogen Amevive NDA Filing For Psoriasis Expected In Second Half Of 2001
Executive Summary
Biogen plans to file an NDA for the T-cell modulator Amevive for psoriasis in the second half of 2001, VP-Medical Research Burt Adelman, MD, said during the company's first quarter conference call April 12.